Elevating Human Health
Featured In
Model Medicines
Innovating at the Intersection of Data Science, Biology and Drug Development
Quarterly Update
Annual Letter
Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs.
With GALILEO™, we've discovered 192 compounds and advanced 67 assets in cellular models of disease across 12 therapeutic targets for multiple areas of biology. Our data was validated by preeminent researchers and scientists at premier academic and corporate laboratories.
The company was founded in La Jolla, CA in 2019 to deliver on the promise of AI-Drug discovery.
AssetS
67
Targets
12
Hit Rate
66.7%
Preclinical Lead assets
2
Investors
Invested in Our Success
We’re backed by leading, multi-stage investors with significant expertise and sophistication in the Bio-IT/pharma space.
Pre-Prints & Papers
Endeavors
Transforming Medicine, One Endeavor at a Time
At Model Medicines, we are committed to addressing the most pressing global health challenges through focused innovation. The Model Medicines Endeavor (MME) program reflects this mission by launching specialized entities that leverage our advanced AI-driven drug discovery platform to target specific disease areas and indications.
The MME program allows us to accelerate the development of transformative medicines by creating focused, agile entities dedicated to distinct therapeutic areas. Each MME benefits from Model Medicines’ proprietary GALILEO™ platform, enabling rapid discovery and development of novel therapeutics.
VIROMME: The first Model Medicines Endeavor focuses on infectious diseases. With a robust pipeline including MDL-001, 12 novel chemical entities, and the groundbreaking discovery of RdRp Thumb-1—a highly conserved allosteric antiviral target—VIROMME is poised to revolutionize how we treat serious viral infections. Learn more at viromme.com
Events
Announcements
